AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa

Plain-language summary

This study examines a gene therapy called AGN-151597 in patients with advanced retinitis pigmentosa (a progressive vision-loss disease). Patients aged 18 and over who are able to comply with the study requirements may take part. The study was conducted in Phase 1/Phase 2 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

PHASE1/PHASE2

Status

Completed

Sponsor

AbbVie

Intervention

AGN-151597

Start date

12/14/2015

Estimated completion

10/21/2024

Countries

United States

Related genes

Locations

• San Francisco, United States
• Edgewood, United States
• Durham, United States
• Dallas, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

Participants must meet all of the following criteria.

1. Age \>= 18 years.
2. Signed and dated written informed consent obtained from the patient.
3. Ability to comply with testing and all protocol tests.

Exclusion Criteria:

Any one of the following will exclude patients from being enrolled into the study:

1. Unable or unwilling to meet requirements of the study.
2. Participation in a clinical study (ocular or non-ocular) with an investigational drug, agent or therapy in the past six months.